Udai Banerji
@udaibanerji.bsky.social
Clinician Scientist, passionate translational medicine and drug discovery in oncology and beyond...
Congratulations to Fisher Lab @ucl.ac.uk on predicting combinations of anticancer drugs, was privileged to be part of the consortium. Executable models offer insights that black box models do not. pubmed.ncbi.nlm.nih.gov/42341181/ @icr.ac.uk @crukconvergence.bsky.social
July 6, 2026 at 11:45 AM
Congratulations to Fisher Lab @ucl.ac.uk on predicting combinations of anticancer drugs, was privileged to be part of the consortium. Executable models offer insights that black box models do not. pubmed.ncbi.nlm.nih.gov/42341181/ @icr.ac.uk @crukconvergence.bsky.social
Research can be all consuming, sometimes you have to stop and look around.....
May 9, 2026 at 4:42 PM
Research can be all consuming, sometimes you have to stop and look around.....
Proximity induced degradation has only just begun!
The @US_FDA approved the protein degrader vepdegestrant for adults with previously treated ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations: buff.ly/B0gPzIW
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutate
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
www.fda.gov
May 2, 2026 at 8:26 PM
Proximity induced degradation has only just begun!
The intersection of the PI3K/AKT pathway and immunotherapy. ICECAP study led by Prof Juanita Lopez. pubmed.ncbi.nlm.nih.gov/42043781/ @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
April 30, 2026 at 4:29 PM
The intersection of the PI3K/AKT pathway and immunotherapy. ICECAP study led by Prof Juanita Lopez. pubmed.ncbi.nlm.nih.gov/42043781/ @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
At #AACR26. Leveraging cancer stroma to deliver anticancer drugs. Fibroblast co-culture experiments in PDAC and sarcoma cell lines to study the role of AVA6000 a FAP activated doxorubicin prodrug as a single agent and in combination. @icr.ac.uk @crukconvergence.bsky.social
April 22, 2026 at 2:34 PM
At #AACR26. Leveraging cancer stroma to deliver anticancer drugs. Fibroblast co-culture experiments in PDAC and sarcoma cell lines to study the role of AVA6000 a FAP activated doxorubicin prodrug as a single agent and in combination. @icr.ac.uk @crukconvergence.bsky.social
At #AACR26 Poster 6457.CD137 agonist. Exciting responses in breast cancer and high spec pharmacodynamic imaging showing decreasing metabolism (FDG-PET) but increasing lymphocytic infiltration (CD8 PET). @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
April 21, 2026 at 2:35 PM
At #AACR26 Poster 6457.CD137 agonist. Exciting responses in breast cancer and high spec pharmacodynamic imaging showing decreasing metabolism (FDG-PET) but increasing lymphocytic infiltration (CD8 PET). @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
At ##AACR26 , great to see the Cancer Therapeutics podium filled by ex Drug Development Unit fellows who are now Profs all across the world! @icr.ac.uk @royalmarsden.org . 👏👏👏
April 19, 2026 at 11:46 PM
At ##AACR26 , great to see the Cancer Therapeutics podium filled by ex Drug Development Unit fellows who are now Profs all across the world! @icr.ac.uk @royalmarsden.org . 👏👏👏
Its a honour to be appointed as a NIHR Senior Investigator. The NIHR has kept research at the forefront of the NHS and allows us to perform patient centric, scientifically robust research. @icr.ac.uk @royalmarsden.org @nihr.bsky.social
March 24, 2026 at 5:36 PM
Its a honour to be appointed as a NIHR Senior Investigator. The NIHR has kept research at the forefront of the NHS and allows us to perform patient centric, scientifically robust research. @icr.ac.uk @royalmarsden.org @nihr.bsky.social
Seville (bitter) oranges some times used for marmalade or juice but not usually edible as an oranges contain furanocumarins, CYP3A4 inhibitors that increase levels of drugs metabolised by CYP3A4.
February 27, 2026 at 4:20 PM
Seville (bitter) oranges some times used for marmalade or juice but not usually edible as an oranges contain furanocumarins, CYP3A4 inhibitors that increase levels of drugs metabolised by CYP3A4.
Fuelling the qest for the next generation of clinician scientists. Great opportunity!
❗One week left to apply for our intercalated #PhD (iPhD) ⌛
If you're a medical student interested in becoming a clinician-scientist, check out our PhD projects for 2026. 👇
If you're a medical student interested in becoming a clinician-scientist, check out our PhD projects for 2026. 👇
🩺 Are you a #MedStudent doing an iBSc? We're looking for future clinician-scientists to join our intercalated #PhD ( #iPhD) programme in 2026.
Explore projects & apply by 20 Nov 👉 bit.ly/48YA5Tp
Please share with your networks!
#CancerResearch #ConvergenceScience #CRUKFunded
Explore projects & apply by 20 Nov 👉 bit.ly/48YA5Tp
Please share with your networks!
#CancerResearch #ConvergenceScience #CRUKFunded
November 13, 2025 at 6:52 PM
Fuelling the qest for the next generation of clinician scientists. Great opportunity!
PhD convocation ceremony at @icr.ac.uk with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised. @trevorgraham.bsky.social
November 1, 2025 at 12:32 PM
PhD convocation ceremony at @icr.ac.uk with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised. @trevorgraham.bsky.social
Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records. pubmed.ncbi.nlm.nih.gov/40855012/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social @nihr.bsky.social
August 29, 2025 at 1:43 PM
Interesting insights into phase I trial recruitment in oncology and health care utilization using data extracted from unstructured text in health care records. pubmed.ncbi.nlm.nih.gov/40855012/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social @nihr.bsky.social
Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite. pubmed.ncbi.nlm.nih.gov/40641211/ @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social
July 14, 2025 at 4:09 PM
Organoid culture is prohibitively expensive. Solution to Harvest Organoids Efficiently (SHOE) allows rapid and inexpensive harvesting of organoids. Please use in your research labs and cite. pubmed.ncbi.nlm.nih.gov/40641211/ @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social
Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads. pubmed.ncbi.nlm.nih.gov/40611310/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social
July 8, 2025 at 10:08 AM
Antibody-drug-conjugate toxicity is real and poorly understood. Looking for trends in association with antibody/linker/payloads. pubmed.ncbi.nlm.nih.gov/40611310/ @icr.ac.uk @royalmarsden.org @ecmc-uk.bsky.social @crukconvergence.bsky.social
Published today @natmed.nature.com www.nature.com/articles/s41...
Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
June 27, 2025 at 10:48 AM
Published today @natmed.nature.com www.nature.com/articles/s41...
Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
Thank you to all patients, families and research staff. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
Published today in @natmed.nature.com www.nature.com/articles/s41... combination of avutometinib and defactinib in LGSOC. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
June 27, 2025 at 10:40 AM
Published today in @natmed.nature.com www.nature.com/articles/s41... combination of avutometinib and defactinib in LGSOC. @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @ecmc-uk.bsky.social
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
@nihr.bsky.social @crukconvergence.bsky.social @cancerresearchuk.org
#MCCR2025. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC @theaacr.bsky.social
June 19, 2025 at 9:05 PM
#MCCR2025. Methods in clinical cancer research workshop hits its 25 year birthday! Fabulous opportunity to train young oncologists to develop research protocols. Especially proud to have been a trainee over 20 years ago and having served as faculty. @ESMO @EORTC @theaacr.bsky.social
Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients. @ecmc.bsky.social @icr.ac.uk @icrdduiit.bsky.social @nihr.bsky.social @cruk.bsky.social
May 7, 2025 at 11:19 AM
Sharing good practice to run complex radio-immuno conjugate trials in the UK to accelerate drug development and improve outcomes of cancer patients. @ecmc.bsky.social @icr.ac.uk @icrdduiit.bsky.social @nihr.bsky.social @cruk.bsky.social
Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer. #AACR2025 @icr.ac.uk
April 29, 2025 at 11:58 PM
Professor Paul Workman, fellow of AACR, talking on the urgency in developing chemical probes to fight cancer. #AACR2025 @icr.ac.uk
End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need. @icr.ac.uk @crukconvergence.bsky.social @nihr.bsky.social @ecmc-uk.bsky.social
April 29, 2025 at 11:51 PM
End of a long day at AACR. Presented using patient derived organoids to understand and refine mechanisms of synergy of avutometinib and defactinb combination in low grade ovarian, an area of unmet need. @icr.ac.uk @crukconvergence.bsky.social @nihr.bsky.social @ecmc-uk.bsky.social
#AACR2025 has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz! @icr.ac.uk @cancerresearchuk.org @nihr.bsky.social
April 25, 2025 at 11:55 PM
#AACR2025 has begun. Educational sessions on plasticity/drug resistance and models of cancer evolution. Feel the buzz! @icr.ac.uk @cancerresearchuk.org @nihr.bsky.social
Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!
February 26, 2025 at 7:00 PM
Happy retirement to my wife Jane, joined nurse training 42 years ago, worked across several NHS trusts and Australian public hospitals on clinical trials of carboplatin, VP16 (etoposide), GCSF, ondansetron and CHART RT in clinic. Worked in tral management @icr since 2005. Time to put up your feet!
www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…
January 24, 2025 at 6:16 AM
www.icr.ac.uk/about-us/icr... Blog about projects @icrlondon.bsky.social in ovarian cancer. Its only the tip of the iceberg, there are many exciting projects too early to talk about! Blessed to be a small cog in the big wheel of progress in cancer research at my institution and beyond…